BridgeBio Pharma announced positive Phase 3 trial results for infigratinib in treating achondroplasia (dwarfism) in children, showing superior annualized height velocity compared to placebo. The company plans to submit FDA and regulatory applications in the second half of 2026. The stock surged 6.92% to $78.41, nearing its 52-week high.

The article identifies 10 stocks positioned to deliver strong returns in 2026 across growth, value, and income categories. These include payment processor Visa, adtech firm The Trade Desk, social media giant Meta, healthcare conglomerate UnitedHealth Group, satellite radio operator Sirius XM, drug developer BioMarin Pharmaceutical, utility NextEra Energy, cybersecurity provider Okta, water utility York Water, and auto parts retailer O'Reilly Automotive. Each stock is highlighted for competitive advantages, attractive valuations, or strong historical performance.

Wall Street traded modestly higher Tuesday with the S&P 500 up 0.4% near 6,900. Strong U.S. GDP data (4.3% annualized growth) prompted traders to scale back Fed rate cut expectations. Novo Nordisk surged 9% following FDA approval of Wegovy in pill form. Precious metals rallied significantly, with silver jumping over 2% to break above $70/ounce (up 140% YTD), gold reaching record highs, and platinum surging 5.5%.

BioMarin Pharmaceutical agreed to acquire Amicus Therapeutics for $4.8 billion on Friday. The acquisition is expected to accelerate revenue growth and be accretive to earnings within 12 months. Analysts view the deal favorably, with Truist Securities raising its price target from $80 to $100. The acquisition adds two revenue-generating rare disease therapies and diversifies BioMarin's portfolio, though longer-term technical trends remain under pressure.

The pulmonary emphysema market is projected to grow steadily by 2034, driven by increasing COPD prevalence, an aging population, and advances in therapeutic treatments. Emerging therapies and innovative drugs are expected to transform the market landscape.

The AAV gene therapy market is projected to grow from $3.85 billion in 2025 to $78.56 billion by 2034, with a 40.1% CAGR. North America leads the market, driven by research investments, technological advancements, and increasing genetic disorder prevalence.

Global Pompe disease treatment market is growing steadily, driven by enzyme replacement therapies and improved diagnostic technologies, with ongoing research into gene therapy and small molecule treatments promising more efficient solutions.

The Motley Fool podcast discusses potential acquisition targets, Tesla's decision to abandon its Dojo supercomputer project, and explores possible buyout candidates in various sectors including tech, pharmaceuticals, and apparel.

BioMarin reported strong Q2 earnings, beating estimates with $1.44 per share and $825.41 million in sales. The company discontinued its preclinical drug candidate BMN 390 but advanced BMN 333 with promising Phase 1 study results, targeting a potential 2030 launch.

BioMarin Pharmaceutical reported strong Q2 2025 financial results, with GAAP revenue of $825 million, exceeding analyst estimates by 16% year-over-year. The company raised full-year guidance, driven by robust performance of VOXZOGO and Enzyme Therapies, and demonstrated significant growth in profitability.

Inozyme Pharma announced the postponement of its 2025 Annual Meeting of Stockholders due to the previously announced acquisition by BioMarin Pharmaceutical Inc. The company is a clinical-stage biopharmaceutical company focused on developing innovative therapeutics targeting the PPi-Adenosine Pathway.

The article discusses the stocks that the author has bought during the first five months of 2025, including Pfizer, PubMatic, Sirius XM, Intel, BioMarin Pharmaceutical, and Fastly. The author believes these stocks are undervalued and have long-term growth potential.